Moleculin Biotech, Inc.

NASDAQ:MBRX

1.13 (USD) • At close March 14, 2025
Bedrijfsnaam Moleculin Biotech, Inc.
Symbool MBRX
Munteenheid USD
Prijs 1.13
Beurswaarde 15,031,825
Dividendpercentage 0%
52-weken bereik 0.398 - 6.24
Industrie Biotechnology
Sector Healthcare
CEO Mr. Walter V. Klemp
Website https://www.moleculin.com

An error occurred while fetching data.

Over Moleculin Biotech, Inc.

Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to

Vergelijkbare Aandelen

Applied Therapeutics, Inc. logo

Applied Therapeutics, Inc.

APLT

0.513 USD

Evogene Ltd. logo

Evogene Ltd.

EVGN

1.43 USD

AVROBIO, Inc. logo

AVROBIO, Inc.

AVRO

1.4 USD

Cocrystal Pharma, Inc. logo

Cocrystal Pharma, Inc.

COCP

1.644 USD

Tempest Therapeutics, Inc. logo

Tempest Therapeutics, Inc.

TPST

0.84 USD

Terns Pharmaceuticals, Inc. logo

Terns Pharmaceuticals, Inc.

TERN

3.18 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)